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RESEARCH ARTICLE Open Access
Anti-tumor effects of everolimus and
metformin are complementary and
glucose-dependent in breast cancer cells
Gerke Ariaans, Mathilde Jalving, Emma Geertruida Elisabeth de Vries and Steven de Jong*
Abstract
Background: Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to
side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract
everolimus-induced hyperglycemia, as well as enhancing anti-cancer efficacy. We investigated the glucose-
dependent growth-inhibitory properties of everolimus, metformin and the combination in breast cancer cell lines.
Methods: The breast cancer cell lines MCF-7, MDA-MB-231 and T47D were cultured in media containing 11 mM or
2.75 mM glucose with 21% or 1% oxygen. Everolimus and metformin treated cells were subjected to cytotoxicity and
clonogenic assays, western blotting, FACS and metabolic measurements.
Results: Everolimus was less effective in MCF7 cells under low glucose conditions compared to high glucose conditions
(IC50 of >50 nM vs 29.1 ± 1.4 nM) in a short-term survival assay, while sensitivity of MDA-MB-231 and T47D cells to
everolimus was lost under low glucose conditions. In contrast, metformin was more effective in low than in high
glucose conditions in MCF7 (IC50 of 1.8 ± 1.2 mM vs >5 mM) and MDA-MB231 cells (1.5 ± 1.3 mM vs 2.6 ± 1.2 mM).
Metformin sensitivity of T47D cells was independent of glucose concentrations. Everolimus combined with metformin
additively inhibited cell survival, clonogenicity, mTOR signaling activity and mitochondrial respiration. These effects were
not the result of enhanced autophagy or apoptosis induction. Similar results were observed under hypoxic conditions.
Conclusion: Metformin-induced effects are additive to the anti-proliferative and colony inhibitory properties of
everolimus through inhibition of mitochondrial respiration and mTOR signaling. These results warrant further in vivo
investigation of everolimus combined with metformin as a putative anti-cancer therapy.
Keywords: Metformin, Everolimus, Glycolysis, Hypoxia, Breast cancer, Metabolism
Background
The mammalian target of rapamycin (mTOR) pathway,
hyperactive in numerous cancer types including breast
cancer, is an attractive therapeutic target. Disappointingly,
mTOR inhibitors only show clinical benefit in selected
settings and efficacy is limited. Moreover, toxicity, includ-
ing fatigue and mucositis limit clinical use [1]. mTOR sig-
naling is central in the integration of cellular signals
involved in growth and cellular energy status [2]. There-
fore, the metabolic context of mTOR inhibition in cancer
cells is essential for understanding and improving its anti-
tumor effects and toxicity profile.
The mTOR protein is the catalytic subunit of two
structurally and functionally different protein complexes:
mTORC1 and mTORC2. mTOR complex 1 (mTORC1)
is sensitive to growth factor signaling, oxygen levels and
nutrient availability. Downstream, mTORC1 inhibits the
transcriptional repressor eukaryotic initiation factor 4B
binding protein (4EBP1), and activates S6 ribosomal protein
(S6), leading to expression of proteins essential for the regu-
lation of cell growth. mTOR complex 2 (mTORC2) regu-
lates AKT activity through phosphorylation and is involved
in cell survival and proliferation. Moreover, mTORC2 in-
duces expression of glycolytic enzymes, pentose phosphate
pathway enzymes and glutaminase and increases cellular
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lipogenesis [3]. Everolimus, the most commonly used
mTOR inhibitor, directly inhibits mTORC1, but also (indir-
ectly) inhibits mTORC2 [4, 5]. This mTORC2 inhibition
may underlie the induction of hyperglycemia in a large pro-
portion of patients treated with everolimus [6, 7]. High glu-
cose levels can stimulate tumor growth in patients and are
associated with resistance to breast cancer chemotherapy
[8, 9]. It is currently unknown whether hyperglycemia
counteracts anti-proliferative effects of everolimus. Cancer
patients on everolimus treatment are regularly treated with
anti-diabetic drugs, especially metformin, to reduce glucose
levels. Metformin is a widely prescribed, well-tolerated, ef-
fective treatment for type 2 diabetes mellitus. Moreover,
epidemiological evidence and retrospective clinical data in-
dicate, that metformin has intrinsic anti-cancer properties
[10, 11]. At the cellular level, metformin inhibits com-
plex I of the mitochondrial respiratory chain leading
to compensatory increases in glycolytic flux and activated
AMP-activated kinase (AMPK) [12]. This results in
growth inhibition of tumor cells through inhibition of
mTOR, cell cycle arrest, activation of autophagy and pos-
sibly apoptosis [13]. Thus, everolimus and metformin both
inhibit mTOR signaling and, moreover, differentially tar-
get tumor cell glucose metabolism.
We hypothesized that the combination of everolimus
and metformin would synergistically inhibit cell growth
in a glucose concentration dependent manner. To test
this hypothesis and predict potential clinical value of the
combination, culture conditions optimally reflecting in-
vivo tumor metabolic circumstances are required. Strik-
ingly, in most in vitro studies, media containing up to
25 mM glucose are used. This is 4–5-fold higher than
the mean fasting blood serum glucose levels of healthy
individuals. Additionally, poorly vascularized areas of tu-
mors may have even lower glucose concentrations and
hypoxia may be present. In the present study, we therefore
investigated the growth inhibitory effects and underlying
signal transduction and metabolic mechanisms of everoli-
mus and metformin treatment alone, and in combination,
at physiological glucose concentrations in hypoxic and
normoxic conditions in breast cancer cell lines.
Methods
Reagents and cell culture
Everolimus (Sigma-Aldrich, Zwijndrecht, The Netherlands)
was dissolved in dimethyl sulfoxide (DMSO) to a concen-
tration of 20 mM and diluted in phosphate buffered saline
(PBS, 0.14 M NaCl, 2.7 mM KCl, 6.4 mM Na2HPO4.2H2O,
1.5 mM KH2PO4, pH 7.2–7.5) prior to use. Metformin
(Sigma-Aldrich, Zwijndrecht, The Netherlands) was
dissolved to a concentration of 1 M in PBS and stored
at −20 °C until use. The human tumor cell lines used were
purchased from the American Type Culture Collection
(ATCC, Manassas, USA). The luminal A MCF-7 (catalog
number HTB-22) and luminal A T47D (catalog number
HTB-133) breast cancer cells were cultured in RPMI con-
taining 11 mM glucose, supplemented with 10% FCS at
37 °C in 5% CO2. Triple negative MDA-MB-231 breast
cancer cells (catalog number HTB-26) [14] were cultured
in DMEM containing 11 mM glucose, supplemented with
10% fetal calf serum (FCS) and 1 mM glutamine at 37 °C
in 5% CO2. Cultures in 5.5 mM glucose were maintained
by adding the appropriate amount of glucose-free RPMI/
DMEM to standard RPMI (all Gibco Thermo Fisher Scien-
tific, Bleiswijk, The Netherlands). Glucose concentrations
in cell culture media were measured using the Accu-Chek
Aviva glucose meter (Roche, Almere, The Netherlands).
Accuracy of measurements of glucose concentrations in
cell culture media was confirmed using a calibration curve
constructed using fresh culture medium with known
glucose concentrations. The detection limit of the
Accu-Check is 0.6 mM glucose. Experiments using
2.75 mM glucose in the cell culture media were performed
using cells that were cultured in 5.5 mM glucose and were
prepared in 2.75 mM glucose containing medium 24 h be-
fore the start of the experiment. For hypoxia experiments,
cells were placed in an incubator with 1% oxygen and 5%
CO2 after the addition of reagents.
Viability assay and colony survival assay
For the viability assays MCF7, T47D and MDA-MB-231
cells were plated at a density of 2000, 2500 or 3000 cells
per well, respectively, in 96 wells plates (4 wells/condi-
tion) and subsequently incubated with metformin and
everolimus at the desired concentrations for 4 days in
the same culture medium, that was also used for cell
culture. For MCF7 and T47D RPMI-media containing
11 or 2.75 mM glucose was used. For MDA-MB-231
DMEM containing 11 or 2.75 mM glucose was used.
After 4 days 20 μl 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide solution (5 mg/ml in PBS) was
added to each well. After 4 h of incubation formazan
crystals were dissolved in 200 μl DMSO and absorption
at 520 nm wavelength was determined with a plate
reader (iMark, BioRad, Veenendaal, The Netherlands).
No major effects of metformin on the relationship be-
tween cell numbers and MTT conversion were observed.
For each experiment MTT results were visually checked
by light microscopy. For the colony survival assay cells
were plated in 6-wells plates. 250 cells/well were plated
and allowed to adhere for at least one hour before treat-
ment. When glucose was replenished, 2.75 mM glucose
was added every other day for in total 3 times to achieve
a total amount of usable glucose of 11 mM during the
course of the experiment. Pilot data demonstrated that
this procedure ensured the presence of relatively stable
glucose levels during the course of the drug treatment.
After 8 days of treatment, cells were fixed and stained
Ariaans et al. BMC Cancer  (2017) 17:232 Page 2 of 13
with Coomassie blue. Colonies consisting of at least 50
cells were counted.
Western blotting analysis
MCF-7 and MDA-MB-231 cells were lyzed in MPER
(Thermo Scientific, Bleiswijk, The Netherlands) and diluted
1:1 with SDS sample buffer (4% SDS, 20% glycerol, 0.5 mol/
l Tris-HCl (pH 6.8), 0.002% bromophenol blue). Lysates
were resolved by SDS-PAGE and transferred to PVDF
membranes. Membranes were incubated overnight at 4 °C
and probed with the following antibodies: rabbit-anti-AKT,
rabbit-anti-pAKT (Thr308), rabbit-anti-S6, rabbit-anti-pS6,
rabbit-anti-4EBP1 (all Cell Signaling Technologies, Leiden,
The Netherlands) in a 1:1000 dilution or anti-HIF1α (BD
Biosciences, Breda, The Netherlands) and mouse-anti-actin
(MP Biomedicals, Santa Ana, USA) in a 1:10,000 dilution.
Primary antibodies were stained using HRP-coupled goat
anti-rabbit or rabbit anti-mouse IgG and developed with
Lumi-Light (Roche, Almere, The Netherlands). Images
were captured with the ChemiDoc MP imaging system
(Bio-Rad, Veenendaal, The Netherlands) and Image Lab
Software.
Quantification of autophagy, reactive oxygen species
(ROS), and cell death
MCF-7 and MDA-MB-231 cells were transfected with a
GFP-LC3 containing retrovirus (kindly provided and de-
veloped by H Folkerts, Department of Experimental
Hematology, University Medical Centre Groningen, the
Netherlands). Upon upregulation of autophagy the LC3-
GFP protein forms aggregates that can be visualized
using fluorescence microscopy. Bafilomycin A1, a known
inhibitor of the late phase of autophagy, efficiently blocks
turnover of autophagic vesicles, thereby increasing LC3-
GFP foci. GFP-LC3 expressing MCF-7 and MDA-MB-231
were grown on cover slips and treated with metformin,
everolimus and 20 nM bafilomycin (Sigma-Aldrich,
Zwijndrecht, The Netherlands) for the indicated duration.
Cells were washed with cold PBS and fixed with 3.7% para-
formaldehyde. Cover slips were mounted on glass plates
using Kaiser’s mounting medium. Fluorescent GFP-LC3
foci per individual cell were counted. Moreover, cleavage of
the LC3 protein was determined using Western Blotting
with an anti-LC3 antibody (Cell Signaling Technology,
Leiden, The Netherlands). ROS measurement was per-
formed using H2DCF (Sigma-Aldrich, Zwijndrecht, The
Netherlands). Hydrogen peroxide treated cells were used
as a positive control. After harvesting by trypsinization,
cells were washed once with PBS and subsequently incu-
bated with 10 μM H2DCF for 30 min at 37 °C. Samples
were washed with cold PBS and analyzed using a FACS-
Calibur (Becton Dickinson, Breda, The Netherlands). Ana-
lysis was performed using Flowing software 2.5 (Informer
Technologies, Inc).
Four days prior to cell death measurements, cells were
plated at the desired density, treated with metformin and
everolimus and supplemented with 2.75 mM glucose (1 M
stock solution) each day. On the day of analysis, cells were
harvested by trypsinization and washed once in calcium-
buffer. Cells were subsequently incubated in a 1:12 dilution
of annexin V-FITC antibody (IQ products, Groningen, The
Netherlands) in calcium buffer for 20 min on ice. Samples
were washed with calcium-buffer and resuspended in
calcium-buffer containing 0.5 μg/ml propidium iodide (PI).
Cells were analyzed immediately using a FACSCalibur
(Becton Dickinson, Breda, The Netherlands). Analysis was
performed using Flowing Software 2.
Quantification analyses of mitochondrial respiration and
glycolysis
Mitochondrial and glycolytic function of MCF7 and
MDA-MB-231 cells was determined using a Seahorse
XF24 Extracellular Flux Analyzer (Seahorse Bioscience,
North Billerica, USA). Cells were seeded with an appro-
priate density in specialized V7 Seahorse tissue culture
plates (3 wells/condition). After 2 days cells were treated
with indicated concentrations of metformin, everolimus
or a combination and incubated for another 2 days. On
the day of the measurements, cells were washed once
with PBS and once with unbuffered 1 mM sodium pyru-
vate containing XF assay medium (pH 7.4) and 11 mM
or 2.75 mM glucose, respectively. The assay commenced
after cells had been incubated in 500 μl unbuffered XF
assay medium (pH 7.4) for 1 h. Baseline oxygen con-
sumption rate (OCR) and extracellular acidification rate
(ECAR) were determined. To gather detailed informa-
tion about the mitochondrial and glycolytic function of
the cell lines MCF-7 and MDA-MB-231 in response to
treatment with metformin and everolimus a mitochon-
drial stress test was performed. Using the ATP-synthase
inhibitor oligomycin, the mitochondrial uncoupler carbonyl
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) the
complex I inhibitor rotenone and the cytochrome C reduc-
tase inhibitor antimycin A (all Sigma-Aldrich, Zwijndrecht,
The Netherlands) a detailed profile of basal respiration,
maximal respiration and induction of glycolysis can be
gathered. Three technical replicates were performed per
sample. OCR and ECAR were normalized for the amount of
cellular protein in each well using the seahorse XF24 soft-
ware. Protein amount was determined using the Bradford
assay. The three measurements of each step of this mito-
chondrial stress test were combined for analysis.
Statistical analyses
Data are presented as mean ± standard deviation (SD). Dif-
ferent experimental conditions were compared using un-
paired Student’s t-tests. Statistical analyses were performed
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using Prism v.5 (GraphPad). A P-value of <0.05 (two-
tailed) was considered significant.
Results
Inhibition of cell viability by everolimus and metformin is
glucose-dependent
In order to determine whether glucose levels have an ef-
fect on the inhibition of cell viability by everolimus and
metformin in a short-term treatment setting of 4 days, an
MTT-based cell survival assay was carried out. Everolimus
inhibited viability of luminal A wild-type p53 MCF7 breast
cancer cells, and to a lesser extent viability of the triple
negative mutant p53 MDA-MB-231, and luminal A mu-
tant p53 T47D breast cancer cells in culture medium con-
taining 11 mM glucose. In culture medium containing
2.75 mM glucose, effects of everolimus on cell viability
were reduced for MCF7 cells and completely lost for
MDA-MB-231 and T47D cells (Fig. 1a-d). Metformin
inhibited viability of all three cell lines in a concentration
dependent manner at both glucose concentrations. Met-
formin treatment of MCF7 and MDA-MB-231 cells was
more effective in 2.75 mM glucose medium than in
11 mM glucose medium (Fig. 1a-d). The effects of everoli-





Fig. 1 Inhibition of cell viability by everolimus and metformin is glucose-dependentMCF-7 (a), MDA-MB-231 (b) and T47D (c) cells cultured in
11 mM or 2.75 mM glucose-containing medium were treated with everolimus (1-50 nM) and/or metformin (1 and 5 mM) for 96 h. Cell viability
was measured using an MTT assay. IC50-values were calculated for everolimus and metformin in high and low glucose conditions (d). Data are
presented as mean ± SD of three different experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; n = 3
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additive in both high and low glucose conditions. Since
everolimus was less effective but metformin more effective
in low glucose conditions, the overall effect of combin-
ation remained the same in high and low glucose condi-
tions (Fig. 1a-d).
The majority of luminal A breast cancers are wild-type
p53 and triple negative breast cancer are frequently mu-
tant p53. Therefore, we used MCF7 and MDA-MB231
as representatives of these breast cancer subtypes for
further analyses.
mTOR inhibition by metformin is dependent on glucose
concentration
Subsequently, we examined the ability of everolimus and
metformin to inhibit mTOR signaling in MCF-7 and
MDA-MB-231 cells in the presence of high and low glu-
cose concentrations using p-S6 levels as read-out for
mTOR signaling. Everolimus inhibited the mTOR sig-
naling pathway in a concentration dependent fashion at
high glucose concentration in MCF7 cells but only mar-
ginally in MDA-MB-231 cells, as demonstrated by the
reduction in p-S6 (Fig. 2a). The effect of everolimus (1
and 10 nM) on p-S6 levels at low glucose concentration
was reduced in MCF7 cells and lost in MDA-MB-231
cells (Fig. 2a). These results are in agreement with the
cell viability assay results (Fig. 1a and b). Metformin (1 and
5 mM) also inhibited the mTOR-signaling pathway in both
MCF-7 and MDA-MB-231 cells in a drug concentration
dependent manner as indicated by reduced p-S6 levels
(Fig. 2b). Metformin more effectively diminished p-S6 levels
in both cell lines at low glucose concentration in concur-
rence with the viability assay results. The combination of
everolimus and metformin resulted in a strong inhibition of
the mTOR pathway at both glucose concentrations in
MCF-7 and MDA-MB-231 cells (Fig. 2c).
As a second read-out for mTOR signaling we used
4EBP1. The lower molecular weight bands probably reflect
less phosphorylated 4EBP1, indicating stronger inhibition
of cap-dependent initiation of mRNA translation by
4EBP1 [15]. A shift in 4EBP1 band intensity from the
higher to the lower molecular weight band was observed
in both cell lines treated with everolimus (Fig. 2a). Metfor-
min also induced a concentration dependent band shift of
4EBP1 in MCF-7 and MDA-MB-231 cells (Fig. 2b). The
combination of everolimus and metformin resulted in a
band shift of 4EBP1, independently of glucose concentra-
tion (Fig. 2c). Taken together, these results suggest an
additive effect of everolimus and metformin on mTOR
pathway inhibition.
Everolimus and metformin do not alter autophagy levels
or ROS formation
Previous research suggests that everolimus and metfor-
min are able to induce autophagy [16]. However, treat-
ment with everolimus, metformin, or a combination of
both drugs did not induce changes in LC3-GFP foci for-
mation in MCF7 and MDA-MB-231 cells (Fig. 3a). In
addition, Western blotting of cleaved LC-3 did not show
increased autophagy due to everolimus and/or metfor-
min treatment at any glucose concentration (Fig. 3b).
LC-3 cleavage was not influenced by oxygen tension
(data not shown). These results indicate that everolimus
and metformin did not interfere in autophagic processes
in these models.
Due to the inhibition of complex I in mitochondria by
metformin, we expected a decrease in the formation of
ROS [17]. Everolimus, metformin or both drugs combined
did not affect ROS formation at the indicated concentra-
tions in MCF7 and MDA-MB-231 cells. In contrast, treat-
ment with the known ROS inducer hydrogen peroxide led
to an increase in cellular H2DCF fluorescence (Fig. 3c-d).
Everolimus reduces mitochondrial respiration, whereas
metformin also increases glycolysis
Figure 4 shows the effects of everolimus and metformin on
mitochondrial respiration (OCR) and glycolysis (ECAR) in
MCF7 and MDA-MB-231 cells. Basal OCR did not signifi-




Fig. 2 Effect of glucose concentration on inhibition of mTOR
signalling by everolimus and metformin. Western Blotting analysis
was carried out for S6, pS6 and 4EBP1. Cells were treated for 2 days
with indicated concentrations of metformin (a), everolimus (b) or a
combination (c) Representative Western Blots are shown
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agreement, everolimus did not induce changes in ECAR.
Metformin dose-dependently reduced basal OCR in MCF7
and MDA-MB-231 cells. In contrast to everolimus treat-
ment, metformin also dose-dependently increased basal
ECAR of MCF7 cells, indicating an induction of glycolytic
processes in response to metformin treatment. This shift
from mitochondrial respiration to glycolysis in MCF7 cells
was most pronounced in high glucose media. A combin-
ation of everolimus and metformin strongly reduced the
OCR/ECAR ratio, even when low doses were used. How-
ever, there is no difference in OCR/ECAR ratio between
metformin treated cells and combination treated cells
suggesting a dominant effect of metformin on cell
metabolism. Another important difference between
the effect of metformin and everolimus is that un-
coupling of the mitochondrial respiration with FCCP
in metformin treated cells resulted in an enhancement
of respiration (Additional file 1: Figure S3). Respiration
levels, however, were still lower than respiration levels in
untreated cells after uncoupling of mitochondrial respir-
ation. Uncoupling with FCCP did not elevate mitochondrial
respiration in everolimus treated cells. This suggests that
metformin treatment inhibits mitochondrial respiration
and partially reduced the mitochondrial capacity, whereas
everolimus treatment resulted in a loss of mitochondrial
capacity.
Metformin does not induce cell death under stable low
glucose conditions
Because metformin increases glycolysis, as measured by
ECAR, we predicted the glucose requirements of
metformin-treated cells to be elevated. This high glucose
demand may lead to glucose starvation in the in vitro
setting and ultimately to apoptosis-mediated cell death.
To quantify cell death, MCF7 and MDA-MB-231 cells
were stained with annexin V and PI to determine cell
death. MCF7 and MDA-MB-231 cells were plated and
treated with everolimus or metformin for 4 days in
media containing either 11 mM or 2.75 mM glucose. In
the presence of metformin, cell death increased from 20
to 50% and from 10 to 70% in MCF7 and MDA-MB-231
cells, respectively, when cells were cultured in media
containing 2.75 mM glucose. No metformin-induced ef-
fect on cell death was observed in media containing
11 mM glucose. Everolimus treatment did not induce




Fig. 3 Metformin and everolimus do not influence autophagy and ROS production. a MCF-7 and MDA-MB-231 cells stably expressing LC3-GFP
cultured in 11 mM and 2.75 mM glucose-containing medium were treated with indicated concentrations of 10 nM everolimus and/ or 5 mM
metformin for 48 h. 20 μM bafilomycin was added 1 h prior to evaluation of the assay. Fluorescent GFP-LC-3 foci per individual cell were counted.
Data are presented as mean ± SD of three different experiments. b MCF-7 and MDA-MB-231 cells cultured in 11 mM and 2.75 mM glucose-containing
medium were treated with everolimus (10 nM) or metformin (5 mM) for 48 h. Western Blotting for LC-3 revealed that there is no increased LC-3
cleavage after either treatment. c MCF-7 cells were treated with 250 μM H2O2 for 1 h. Hydrogenperoxide induces ROS production in
MCF-7 cells, as demonstrated by increase in cellular H2DCF fluorescence. d MCF-7 and MDA-MB-231 cultured in 11 mM or 2.75 mM glucose-containing
medium were treated with indicated concentrations of everolimus or metformin for 48 h, and stained with 10 μM H2DCF. Everolimus and metformin do
not induce significant changes in ROS levels compared to untreated cells. Data are presented as mean ± SD of three different experiments
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11mM glucose 2.75mM glucose
MCF-7
MDA-MB-231
Fig. 4 Oxygen consumption and extracellular acidification after treatment with metformin and everolimus for 48 h. Using the seahorse XF analyzer, the
OCR, the ECAR and the ratio of both parameters of MCF-7 (a) and MDA-MB-231 cells (b) in response to 48 h of metformin or everolimus treatment was
determined. Data are presented as mean ± SEM of three different experiments. Treated samples were compared to the same glucose concentration
control. * p < 0.05; ** p < 0.01; *** p < 0.001; n = 3
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To gain further insight in these glucose concentration-
dependent cell death induced by metformin, we monitored
glucose concentrations in culture media in time. The initial
glucose concentration of 11 mM dropped faster following
treatment of MCF7 cells with 5 mM metformin compared
to no metformin (Additional file 2: Figure S1), which is in
agreement with enhanced ECAR. The enhancing effect of
metformin treatment on glucose consumption was less evi-
dent with MDA-MB231 cells. After 3 days of metformin
treatment glucose was still detectable in culture media of
both cell lines. In media with 2.75 mM glucose, levels
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Fig. 5 Metformin can only induce cell death under glucose-deprived conditions. MCF-7 (a) and MDA-MB-231 (b) cells were plated in medium
containing 11 mM or 2.75 mM glucose and were treated with indicated concentrations of metformin and everolimus for 4 days. In addition, cells
plated in 2.75 mM glucose were also replenished with 2.75 mM glucose every day (2.75 mM glucose replenished). AnnexinV/PI staining was used
to quantify the percentage of dead cells after 4 days. Glucose concentration in the culture medium was determined after 4 days. The dashed line
indicates the detection limit of the glucose meter. Data are presented as mean ± SD of three different experiments. Treated samples were compared
to the same glucose concentration control. * p < 0.05; ** p < 0.01; *** p < 0.001
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Fig. 6 Hypoxia affects the efficacy of metformin only during short-term experiments. a MCF-7 and MDA-MB-231 cultured in 11 mM or 2.75 mM
glucose-containing medium were treated with indicated concentrations of everolimus and metformin under normoxic or hypoxic conditions.
Glucose was not replenished throughout the treatment. Cell viability was measured after 96 h using an MTT assay. Hypoxia alone already
decreased cell viability to 50% of the viability in normoxia. Data are presented as mean ± SD of three different experiments. * p < 0.05; ** p < 0.01;
*** p < 0.001. b MCF-7 cells cultured in 11 mM or 2.75 mM glucose-containing medium were treated with indicated concentrations of everolimus
and metformin under normoxic or hypoxic conditions for 48 h. Western Blotting was carried out for HIF1a, S6 and p-S6. A representative blot of 2
experiments is shown. c MCF-7 cells were plated in medium containing 11 mM or 2.75 mM glucose at a concentration of 500 cells/well. After 8 days
of treatment, MCF7 colonies, consisting of at least 50 cells, were counted. MCF7 cells were treated with indicated concentrations of metformin +/−
everolimus (10 nM). Data are presented as mean + SD of three different experiments
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reduction in glucose levels below 0.6 mM was observed in
media from cells treated with metformin, which is in line
with the observed cell death (Additional file 2: Figure S1,
Fig. 5a-b). In an additional set up, cells were therefore
plated in 2.75 mM glucose containing media and each day
supplemented with 2.75 mM glucose. Glucose concentra-
tions were effectively kept above 0.6 mM during the 4 days
metformin treatment, and the treatment did not result in
cell death (Additional file 2: Figure S1, Fig. 5a-b).
These results demonstrated that metformin-induced
cell death of MCF7 and MDA-MB-231 cells was due to
glucose exhaustion and not due to low glucose culture
conditions per se.
Hypoxia does not influence the efficacy of everolimus
and metformin during long-term treatment
Hypoxia is often observed in tumors. Under hypoxic
conditions mitochondrial respiration and ATP produc-
tion are compromised and cells are forced to use gly-
colysis, which may reduce the efficacy of metformin as
mitochondrial inhibitor in these cells. Since hypoxia and
low glucose concentrations have been found to co-occur
in the same regions of a tumor [18], we tested the effi-
cacy of metformin on cells cultured in 2.75 mM glucose
combined with hypoxia. Hypoxia only modestly affected
cell survival compared to survival under normoxic con-
ditions, indicating that cells were still proliferating. How-
ever, effect of metformin on survival was lost in hypoxic,
low glucose conditions in a short-term assay (Fig. 6a).
Western Blotting of hypoxia inducible factor 1 α (HIF1α)
confirmed hypoxic culture conditions. Cellular p-S6 levels
in hypoxic conditions were reduced in 11 mM glucose
and almost lost in 2.75 mM glucose containing media
(Fig. 6b). Because the effect of hypoxia on p-S6 was so
strong in 2.75 mM glucose containing media, no further
reduction in p-S6 with everolimus or metformin treat-
ment could be visualized.
Glucose concentration and hypoxia do not affect inhibition
of colony formation by everolimus and metformin
Next, we investigated the relationship between colony
forming capacity and glucose concentration, hypoxia
and inhibitory effects of everolimus and metformin.
MCF7 cells were used in this long-term assay, since
these cells developed easy measurable colonies. Everoli-
mus and metformin both inhibited colony formation in a
concentration dependent manner (Fig. 6c and Additional
file 3: Figure S2). The glucose concentration in clonogenic
assay media had no effect on the colony forming capacity
of the cells or the inhibitory effects of everolimus and
metformin. Replenishment with 2.75 mM glucose at a 2-
day interval to prevent glucose shortage during the course
of this long-term experiment did not change the results
(Additional file 3: Figure S2). This is in agreement with
the observation that the glucose concentration of the
medium did not change considerably within the
course of the clonogenic experiment at any condition
(data not shown). Colony formation was also not affected
by hypoxia. Moreover, efficacy of everolimus and metfor-
min was similar in normoxia and hypoxia, both in low
and high glucose conditions in the clonogenic assay
(Fig. 6c). These results explain why the combination of
everolimus and metformin had a strongly additive inhibi-
tory effect on colony formation under all circumstances
(Fig. 6c and Additional file 3: Figure S2).
Discussion
In the present study, we show that everolimus and
metformin both inhibit mTOR activity and have additive
inhibitory effects on glucose metabolism, tumor cell
growth and colony formation. These effects are evident
in high and low glucose conditions and not reduced in
the presence of hypoxia. These results support further in
vivo investigation of everolimus combined with metfor-
min as a putative anti-cancer therapy.
We found that the inhibitory effects of metformin on
growth and colony formation of breast cancer cells were
additive to the effects of everolimus in high and low glu-
cose conditions, even when relatively low concentrations
of both drugs were used. A previous study with different
mutant p53 breast cancer cell lines cultured in high glu-
cose media, demonstrated efficacy of metformin even at
lower concentrations in both MTT and mammosphere
assays, while higher concentrations of everolimus were
required compared to our study [19]. Wang et al. also
showed in vivo efficacy of the combination in xenograft
bearing mice. Metformin sensitivity has been related to
the presence of mutant p53 [20] and everolimus sensitiv-
ity to the presence of wild type p53 [21]. In our cell line
panel, everolimus was indeed effective in wild-type p53
cells (MCF7) and less effective in mutant p53 cells
(MDA-MB231 and T47D), but the preferential sensitivity
of metformin in mutant p53 cells was not observed. Thus,
more studies are required to investigate metformin and
everolimus sensitivity in relation to the p53 status in
breast cancer models. Interestingly, the combination of
everolimus and metformin effectively inhibited colony and
mammosphere forming capacity of wild type and mutant
p53 breast cancer cells [Fig. 6c], [19]. These results suggest
that tumor initiating cells are also sensitive to this com-
bination in addition to bulk tumor cells as measured in
the MTT assay, making this combination even more at-
tractive to be further explored in breast cancer.
The inhibitory effect on mTOR has been described for
each drug individually [22]. Here, we demonstrate that
mTOR signaling is additively inhibited by the combination
treatment. For everolimus it was expected that reduced
mTOR activation would lead to reduced transcription of
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glycolytic enzymes and therefore a shift to mitochondrial
respiration [23]. In contrast, we observed that everolimus
inhibits mitochondrial respiration, which was not
compensated by an enhanced glycolysis rate, as previ-
ously reported for hepatocellular carcinoma cells as
well [24]. In human pancreatic cancer cell lines, how-
ever, everolimus treatment reduced the rate of gly-
colysis. Unfortunately, the effect on mitochondrial
respiration was not reported [25]. At a mechanistic
level, it has been shown that mTOR stimulates trans-
lation of mitochondrial mRNAs by inhibiting 4EBPs
[26]. Consequently, mTORC1 inhibition leads to less
mitochondrial mRNA translation and less mitochon-
drial respiration, which is in agreement with our re-
sults that everolimus treatment resulted in reduced p-
S6 levels and mitochondrial respiration in both MCF7
and MDA-MB231 cells. As expected treatment with
the mitochondrial complex I inhibitor metformin
inhibited mitochondrial respiration and induced gly-
colysis [27–29]). Metformin treated cells had also a
reduced maximal respiratory capacity. This might be
an indirect effect of the reduced mTORC1 activity
caused by metformin treatment. The additive meta-
bolic effect of everolimus combined with metformin
has not been described before. Our metabolic mea-
surements show that a combination of both drugs,
even at relatively low concentrations, completely re-
duced p-S6 and disrupted mitochondrial respiration.
Moreover, similar results were obtained in high and
low glucose containing media.
We demonstrate that metformin can induce a meta-
bolic shift to increased glycolysis. The increased glucose
utilization in the presence of metformin, especially
under low glucose conditions, results in an earlier onset
of glucose starvation and more cell death in MCF7 and
MDA-MB231 breast cancer cells. This finding is in ac-
cordance with previous reports using glucose-free cul-
ture conditions [28, 30–32]. Here, we show that under
stable low glucose conditions, thus preventing glucose
starvation by replenishment of glucose, metformin treat-
ment still results in growth inhibition, but cell death
does not occur. Since glucose concentrations are rela-
tively stable in vivo, our model under stable low glucose
conditions in this respect is likely to reflect the situation
in tumors in vivo [33, 34]. This is indirectly supported
by in vivo observations showing that tumors from
metformin treated patients did not have increased
numbers of apoptotic cells compared to placebo
treated patients [35]. Previous in vitro studies in
breast cancer cell line models identified apoptosis as
a mechanism of metformin’s anti-cancer effects. Un-
fortunately, glucose concentrations were not measured
[22, 36, 37]. Our results strongly suggest that these
findings were likely to be caused by in vitro glucose
starvation due to metformin-induced increases in glu-
cose utilization.
Other tumor-microenvironmental factors such as
intratumoral pH, glutamine concentration, and oxygen
tension are likely to influence the in vivo efficacy of met-
formin [38, 39]. Like metformin treatment, hypoxia
shifts cellular metabolism towards glycolysis. This effect
could either lead to synergy or reduce metformin effects,
as shown in a sarcoma cell line model [39]. However,
the sarcoma cell line study CoCl2 was used as a hypoxia
mimetic in a short-term assay. We demonstrate that al-
though in in vitro short-term experiments the effects of
metformin in hypoxic conditions appeared to be reduced,
longer-term assays showed that metformin activity is
maintained. In the short-term setting, hypoxia alone
already decreased cell proliferation, so that possible effects
of metformin on proliferation were harder to detect. In-
deed, we found that p-S6 had almost completely disap-
peared under hypoxic, low glucose conditions suggesting
that these cells were not actively proliferating. During the
long-term clonogenic assay, cells sufficiently adapted to
hypoxia and formed colonies. Metformin was effective
against these colonies under hypoxic conditions, suggest-
ing that metformin will retain its efficacy in the hypoxic
areas of an in vivo tumor.
Blood plasma levels of metformin in patients (around
0.05 mM) are at least twenty-fold lower than those used
in most in vitro cell line studies (1–40 mM) [40]. Al-
though there is evidence that the acidophilic properties of
metformin may cause accumulation in the mitochondrial
matrix, thereby decreasing the systemic levels required,
the low concentrations which potentiate everolimus in
our model are promising [41].
Treatment of cancer cells with inhibitors of both gly-
colysis and mitochondrial respiration, leading to synthetic
metabolic lethality is a promising therapeutic strategy to
kill cancer cells. Combination of metformin with the
glycolytic inhibitor dichloroacetate effectively induced cell
death in breast and ovarian cancer cell lines [27]. Also in
vivo combination treatment with the mitochondrial
inhibitor phenformin and the lactate dehydrogenase
inhibitor oxamate has been successful [42]. Combining
metformin with everolimus is a novel example of dual
metabolic targeting.
Conclusions
Metformin and everolimus had additive inhibitory ef-
fects on both proliferation and colony formation in vitro
in breast cancer cell line models at high and low glucose
concentrations in normoxia and hypoxia. Mechanistically,
mTOR inhibition and dual metabolic targeting appear im-
portant. Metformin can be used to prevent and/or treat
everolimus-induced hyperglycemia, while potentially en-
hancing the anti-cancer effects of everolimus.
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Additional files
Additional file 1: Figure S3. Uncoupling of the mitochondrial
respiration with FCCP after treatment with metformin and everolimus for
48 h. Using the seahorse XF analyzer, the basal OCR and maximal OCR
after uncoupling of mitochondrial respiration with FCCP of MCF-7 (A) and
MDA-MB-231 cells (B) in response to 48 h of metformin or everolimus
treatment was determined. Basal OCR in untreated cells was set at 100%
as a reference to which all other mitochondrial respiration values of the
same glucose concentration group were correlated. Data are presented
as mean ± SD of three different experiments. (PDF 69 kb)
Additional file 2: Figure S1. Glucose concentration of cell culture
medium during 4 days of metformin treatment. MCF-7 and MDA-MB-231 cells
were plated at a concentration of 30.000 (MCF-7) or 80.000 (MDA-MB-231)
cells in medium containing 11 mM or 2.75 mM glucose. Additionally, cells
were plated in medium containing 2.75 mM glucose and replenished with
2.75 mM glucose every 24 h (2.75 mM glucose replenished). Cells were treated
with 5 mM metformin for 4 days. 20 μl medium samples were taken for
glucose concentration measurements every day. In the glucose-
supplemented condition, this was done after addition of glucose. Data are
presented as mean ± SD of three different experiments. (PDF 35 kb)
Additional file 3: Figure S2. Metformin and everolimus inhibit colony
formation of breast cancer cell lines independently of glucose concentration.
MCF-7 cells were plated in medium containing 11 mM or 2.75 mM glucose
at a concentration of 500 cells/well. A subset of cells plated in 2.75 mM
glucose was also replenished with 2.75 mM glucose every 48 h (2.75 mM
glucose replenished). Cells were treated with indicated concentrations of
everolimus and metformin for 8 days and colonies were counted. Data are
presented as mean ± SD of three different experiments. (PDF 33 kb)
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